Skip to main content

      Innovation

      Informing and evaluating new health care solutions

      A woman at a digital board displaying data

      Staying ahead of health care trends and new therapies

      Innovation drives new methods and therapies to treat conditions that sometimes were previously untreatable. Our research informs and evaluates innovative solutions that engage patients and members in their care, reduce costs and reveal insights that help providers, employers and consumers navigate the evolving pipeline of innovative therapies.

      Driving innovation to improve health care

      $908M

      Client gross savings* achieved by replacing Humira from the standard Caremark national commercial formulary with a biosimilar

      6x

      More total weight loss* for CVS Weight Management™ program members who had struggled to lose weight on medication alone

      50%+

      Of CVS Specialty® prescriptions are processed without additional paperwork using electronic health record connectivity*

      Featured research

      White paper

      The importance of biosimilars in health care

      White paper

      Gene therapies and genetically modified cellular therapies: Balancing access, coverage and affordability

      Conference abstract

      Real-world evaluation of oncolytic biosimilar adoption on medication adherence and out-of-pocket costs among members of a national payor

      Conference abstract

      Personalized multichannel educational messaging reduces 30-day hospital readmission rates in the Medicare population

      • *FOR CLIENT GROSS SAVINGS SOURCE: CVS Health Analytics, 2024. CVS Commercial Book of Business clients with standard template formularies (i.e., ACSF, Value, SCF, and BCF), excluding restricted clients, January 2024 – September 2024. All data sharing complies with applicable law, our information firewall and any applicable contractual limitations. Gross savings projections are based on CVS Caremark data. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors. $0 out-of-pocket costs for members enrolled in a plan’s standard template formulary with intelligent benefit design.

      • *FOR MORE TOTAL WEIGH LOSS SOURCE: CVS Health Analytics, 2024. Weight Management Pilot Results. Data from August 2023 through June 2024, 265K total covered lives, as of May 31, 2024. Reflects relative increase in total weight loss from weight management medication start before and after enrollment in CVS Weight Management.

      • *FOR USING ELECTRONIC HEALTH RECORD CONNECTIVITY SOURCE: CVS Health Enterprise Analytics, April 15, 2020. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors. CVS Specialty Expedite is available exclusively for providers who use compatible EHR systems that participate in the Carequality Interoperability Framework or have an eligible EHR with CVS Health-enabled data connections and a fully executed connectivity agreement. All data sharing and usage complies with applicable privacy laws. Some payors have specific utilization management requirements related to PA submissions (e.g., review, submission and/or physical signature by prescribers). CVS Specialty Expedite is only used where permissible by payor requirements and applicable law.